Edesa Biotech, Inc.
corporate_fare Company Profile
Edesa Biotech, Inc. (NASDAQ:EDSA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 32 items for EDSA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-17, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for EDSA spans 8-K, SCHEDULE 13D/A, 424B5, 10-Q.
Recent high-impact activity:
- Edesa Wins EU Orphan Designation for Paridiprubart in ARDS
- Edesa Licenses Paridiprubart in Japan to Kyorin for $12M Upfront, Up to ~$134M Milestones
- $12M Upfront, Up to $134M Milestones: Kyorin Licenses Edesa's ARDS Drug for Japan
- Edesa Triples Executive Pay: CEO Salary to $657,423, CFO to $525,938
- FDA Clears Edesa's IND for EB06 Vitiligo Phase 2; U.S. Enrollment Starts Next Quarter
Financial Snapshot
Short Interest & Short Volume
4.02 days to coverFINRA reported short interest of 158,091 shares in EDSA as of the October 30, 2026 settlement, a 2.0% decrease from the prior period — about 4.0 days to cover at its recent average daily volume. On November 20, 2026, 37.7% of EDSA volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for EDSA, detected from its recent SEC filings · based on capital-structure filings through 2026-08-20.
$25M Offering Priced at 17% Discount · Warrant Structure Adds Overhang
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →